Full Paper
Structural Requirements for the Antiproliferative Activity of Pre-mRNA Splicing Inhibitor FR901464
Article first published online: 19 NOV 2010
DOI: 10.1002/chem.201002402
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Additional Information
How to Cite
Osman, S., Albert, B. J., Wang, Y., Li, M., Czaicki, N. L. and Koide, K. (2011), Structural Requirements for the Antiproliferative Activity of Pre-mRNA Splicing Inhibitor FR901464. Chem. Eur. J., 17: 895–904. doi: 10.1002/chem.201002402
Publication History
- Issue published online: 12 JAN 2011
- Article first published online: 19 NOV 2010
- Manuscript Received: 19 AUG 2010
Funded by
- NIH. Grant Number: S10RR017977-01
- US National Cancer Institute. Grant Number: R01 CA120792
Keywords:
- cancer;
- FR901464;
- meayamycin;
- natural products;
- structure–activity relationships
Abstract
FR901464, a natural product isolated from a bacterium source, activates a reporter gene, inhibits pre-mRNA splicing, and shows antitumor activity. We previously reported the development of a more potent analogue, meayamycin, through the total synthesis of FR901464. Herein, we report detailed structure–activity relationships of FR901464 that revealed the significance of the epoxide, carbon atoms in the tetrahydropyran ring, the Z geometry of the side chain, the 1,3-diene moiety, the C4-hydroxy group, and the C2′′-carbonyl group. Importantly, the methyl group of the acetyl substituent was found to be inessential, leading to a new potent analogue. Additionally, partially based on in vivo data, we synthesized and evaluated potentially more metabolically stable analogues for their antiproliferative activity. These structural insights into FR901464 may contribute to the simplification of the natural product for further drug development.

1521-3765/asset/2111_left.gif?v=1&s=0561086440e3dfc935e925fa17e4b4c8a50bbfe3)
1521-3765/asset/2111_right.gif?v=1&s=9fa3626b72da80da2a89f547de4d2cc5d7fadfe6)
